Literature DB >> 30973731

Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.

Tom D Heightman1, James F Callahan2, Elisabetta Chiarparin1, Joseph E Coyle1, Charlotte Griffiths-Jones1, Ami S Lakdawala2, Rachel McMenamin1, Paul N Mortenson1, David Norton1, Torren M Peakman1, Sharna J Rich1, Caroline Richardson1, William L Rumsey2, Yolanda Sanchez2, Gordon Saxty1, Henriëtte M G Willems1, Lawrence Wolfe2, Alison J-A Woolford1, Zining Wu2, Hongxing Yan2, Jeffrey K Kerns2, Thomas G Davies1.   

Abstract

The KEAP1-NRF2-mediated cytoprotective response plays a key role in cellular homoeostasis. Insufficient NRF2 signaling during chronic oxidative stress may be associated with the pathophysiology of several diseases with an inflammatory component, and pathway activation through direct modulation of the KEAP1-NRF2 protein-protein interaction is being increasingly explored as a potential therapeutic strategy. Nevertheless, the physicochemical nature of the KEAP1-NRF2 interface suggests that achieving high affinity for a cell-penetrant druglike inhibitor might be challenging. We recently reported the discovery of a highly potent tool compound which was used to probe the biology associated with directly disrupting the interaction of NRF2 with the KEAP1 Kelch domain. We now present a detailed account of the medicinal chemistry campaign leading to this molecule, which included exploration and optimization of protein-ligand interactions in three energetic "hot spots" identified by fragment screening. In particular, we also discuss how consideration of ligand conformational stabilization was important to its development and present evidence for preorganization of the lead compound which may contribute to its high affinity and cellular activity.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30973731     DOI: 10.1021/acs.jmedchem.9b00279

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability.

Authors:  Phillip R Lazzara; Brian P David; Aparna Ankireddy; Benjamin G Richardson; Katherine Dye; Kiira M Ratia; Sekhar P Reddy; Terry W Moore
Journal:  J Med Chem       Date:  2019-11-14       Impact factor: 7.446

Review 2.  The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health.

Authors:  Maximillian Taro William Lee; William Mahy; Mark David Rackham
Journal:  RSC Med Chem       Date:  2021-06-04

3.  Nrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction.

Authors:  Sumi Lee; Longqin Hu
Journal:  Med Chem Res       Date:  2020-04-10       Impact factor: 1.965

4.  Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation.

Authors:  Jieli Wei; Fanye Meng; Kwang-Su Park; Hyerin Yim; Julia Velez; Prashasti Kumar; Li Wang; Ling Xie; He Chen; Yudao Shen; Emily Teichman; Dongxu Li; Gang Greg Wang; Xian Chen; H Ümit Kaniskan; Jian Jin
Journal:  J Am Chem Soc       Date:  2021-09-14       Impact factor: 16.383

5.  A hydrogen peroxide responsive prodrug of Keap1-Nrf2 inhibitor for improving oral absorption and selective activation in inflammatory conditions.

Authors:  Mengchen Lu; Xian Zhang; Jing Zhao; Qidong You; Zhengyu Jiang
Journal:  Redox Biol       Date:  2020-05-11       Impact factor: 11.799

Review 6.  Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications.

Authors:  Nancy Vargas-Mendoza; Ángel Morales-González; Mauricio Morales-Martínez; Marvin A Soriano-Ursúa; Luis Delgado-Olivares; Eli Mireya Sandoval-Gallegos; Eduardo Madrigal-Bujaidar; Isela Álvarez-González; Eduardo Madrigal-Santillán; José A Morales-Gonzalez
Journal:  Biomedicines       Date:  2020-05-14

7.  Potent Natural Antioxidant Carveol Attenuates MCAO-Stress Induced Oxidative, Neurodegeneration by Regulating the Nrf-2 Pathway.

Authors:  Imran Malik; Fawad Ali Shah; Tahir Ali; Zhen Tan; Abdullah Alattar; Najeeb Ullah; Arif-Ullah Khan; Reem Alshaman; Shupeng Li
Journal:  Front Neurosci       Date:  2020-06-26       Impact factor: 4.677

Review 8.  Targeting NRF2 to treat cancer.

Authors:  Jared Sivinski; Donna D Zhang; Eli Chapman
Journal:  Semin Cancer Biol       Date:  2021-06-05       Impact factor: 15.707

9.  Query-guided protein-protein interaction inhibitor discovery.

Authors:  Sergio Celis; Fruzsina Hobor; Thomas James; Gail J Bartlett; Amaurys A Ibarra; Deborah K Shoemark; Zsófia Hegedüs; Kristina Hetherington; Derek N Woolfson; Richard B Sessions; Thomas A Edwards; David M Andrews; Adam Nelson; Andrew J Wilson
Journal:  Chem Sci       Date:  2021-03-02       Impact factor: 9.825

Review 10.  Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors.

Authors:  Chung-Hang Leung; Jia-Tong Zhang; Guan-Jun Yang; Hao Liu; Quan-Bin Han; Dik-Lung Ma
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.